Synageva BioPharma Corp Director Barry D. Quart Sells 1,000 Shares (GEVA)
Synageva BioPharma Corp (NASDAQ:GEVA) Director Barry D. Quart sold 1,000 shares of the stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $83.31, for a total transaction of $83,310.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Synageva BioPharma Corp (NASDAQ:GEVA) traded up 5.73% during mid-day trading on Monday, hitting $88.07. 243,662 shares of the company’s stock traded hands. Synageva BioPharma Corp has a one year low of $39.80 and a one year high of $119.42. The stock has a 50-day moving average of $83.33 and a 200-day moving average of $83.90. The company’s market cap is $2.908 billion.
Synageva BioPharma Corp (NASDAQ:GEVA) last announced its earnings results on Friday, May 2nd. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.93 EPS for the current fiscal year.
A number of analysts have recently weighed in on GEVA shares. Analysts at Leerink Swann reiterated a “market perform” rating on shares of Synageva BioPharma Corp in a research note on Thursday, May 15th. They now have a $89.00 price target on the stock, down previously from $101.00. Separately, analysts at Nomura cut their price target on shares of Synageva BioPharma Corp from $144.00 to $140.00 in a research note on Thursday, May 1st. They now have a “buy” rating on the stock. Finally, analysts at Janney Montgomery Scott upgraded shares of Synageva BioPharma Corp from a “neutral” rating to a “buy” rating in a research note on Thursday, May 1st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $108.29.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.